News Archive

News 2022

Kappa Bioscience strengthens its Scientific and Medical Advisory Board with newly appointed member
August 17, 2022

Kappa Bioscience, the leading manufacturer of vitamin K2 under the brand name K2VITAL, has announced the appointment of Dr John E. Repine MD as the newest member of its “Blue Ribbon” Scientific and Medical Advisory Board.

Read more

Vitamin K2 MK-7 with cis bonds – a key that doesn’t fit
July 18, 2022

Understanding vitamin K2 cis- vs trans-bonds impact on product quality.

Read more

The perfect pair: how vitamins K2 and D3 combine to support health and well-being
July 14, 2022

The world is full of iconic duos that combine to become more than the sum of their parts. One relatively unknown yet equally powerful partnership is that of vitamins D3 and K2.

Read more

Balchem Corporation completes acquisition of Kappa Bioscience
June 22, 2022

Kappa Bioscience, the leading manufacturer of vitamin K2 under the brand name K2VITAL, announces that the previously announced acquisition from Balchem Corporation is now complete.

Read more

Balchem signs definitive agreement to acquire Kappa Bioscience
June 15, 2022

Balchem Corporation, a global specialty ingredients company focused on nutrition and health, has signed a definitive agreement to acquire Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway

Read more

Kappa at Vitafoods 2022
May 19, 2022

Kappa Bioscience to discuss vitamin K2 and D synergy at Vitafoods

Read more

Kappa Bioscience® strengthens U.S. presence
April 5, 2022

Kappa Bioscience announces the appointment of Rena Cohen-First as Vice President of Sales North America.with new Vice President of sales in North America

Read more

Kappa Bioscience: Announces the formation of SMAB
March 1, 2022

Kappa Bioscience announced today the formation of a "Blue Ribbon" Scientific and Medical Advisory Board to support and expand the scientific knowledge base for Vitamin K2.

More details

Effects of Vitamin D and K on Interleukin-6 in COVID-19
January 17, 2022

A research group from the Canisius-Wilhelmina Hospital in The Netherlands, in collaboration with Kappa Bioscience, published an article in the medical journal Frontiers in Nutrition.

Research article

News 2021

Kappa Bioscience announces international expansion
February 4, 2021

Kappa Bioscience, Norway-based company and global leader for pure and stable vitamin K2 MK-7, K2VITAL® ingredients, is expanding its business in the United States.

Press release

Kappa Bioscience to extend partnership with Canisius Wilhelmina Hospital
February, 26 2021

The company announces a new agreement with Canisius Wilhelmina Hospital, Nijmegen, The Netherlands, that covers funding of a PhD grant and execution of a clinical trial.

Press Release

Kappa Bioscience’s team goes climate-positive, partners with Ecologi
April 22, 2021


The Norwegian company recently announced its entire workforce went climate-positive from 2021 onwards. Through its cooperation with Ecologi, the company offers its employees to balance their carbon emissions – and more.

Press release

Study confirms correlation between low vitamin K status and severe COVID-19
June 17, 2021

A new study, supported by Kappa Bioscience, confirms that vitamin K status is lower in hospitalized patients with COVID-19, compared to healthy population control. Researchers also show low vitamin K status to be predictive of higher mortality.

Press release

Scientists reveal new K2 knowledge, funded by Kappa Bioscience at this year’s NBJ summit
July 21, 2021

On 29 July, the coming NBJ summit will focus on two key themes: climate action and immune health. Kappa Bioscience, global authority for vitamin K2 MK-7 ingredients, is sponsoring the event, in line with their recent developments.

Press release

Kappa Bioscience announces the industry’s first ‘Brand & Plant’ program
August 30, 2021

Following a recent IPCC publication, Norwegian vitamin K2 expert Kappa Bioscience reveals a resolute ‘Brand & Plant’ program.

Press release

New Kappa Bioscience-funded study uncovers deficiencies in vitamins K and D to be independently associated with COVID-19 disease severity
October 21, 2021

A new study, supported by Kappa Bioscience but conducted independently, shows vitamins K and D could play independent roles in the COVID-19 pathogenesis.

Press release

Norwegian Contract Research Organization Synthetica becomes Kappa Solutions as of November 2021
November 3, 2021


The Kappa Bioscience Group introduces Kappa Solutions, its subsidiary for custom organic synthesis and analytical services for the pharmaceutical and dietary supplements industries. The Norwegian leader for vitamin K2 ingredients renames its sister company, previously known as Synthetica, now Kappa Solutions.

Press release